Based on a recent report published by the Associated Press, a drug that is usually given to patients suffering from Alzheimer is believed to stabilize brain plaque. After ingesting the medicine for a determined period of time, doctors noticed a significant improvement in the condition of their patients.
As scientists were performing new tests for their newly launched Alzheimer related drugs they discovered that the treatment could improve other brain affections, as well. The majority of the respondents who received the drug registered less brain damage than those who were given a dummy treatment.
The drug, named bapineuzumab, is produced by Pfizer Inc. and Johnson & Johnson. While further tests need to be performed in the future, scientists believe the medicine could register great results if it is administered before the brain is completely damaged by diseases like Alzheimer and Parkinson. Unfortunately, doctors did not observe any improvements in the condition of dementia patients in the near term.
Dr. Reisa Sperling, director of the Alzheimer’s center at Brigham and Women’s Hospital in Boston was very satisfied with the results registered by the pill. She told the press that patients went through repeated brain imaging and spinal fluid tests which proved that the medicine was “doing something to the biology of the disease”.
The next move that scientists will make is to test the treatment on patients with mild symptoms of dementia. About 15-20 percent people diagnosed with mild mental impairment or traces of plaque on brain imaging develops Alzheimer’s disease each year.
Many studies have been performed in order to find a treatment for dementia as there are 35 million people worldwide suffering from this disease. The most common form of dementia is Alzheimer, but recent researches were unable to provide answers to doctors’ questions.
Sperling thinks the new tests represent important findings for this medical field. Bapineuzumab was tested many times before, but scientists didn’t notice until now that the drug has better results on patients with incipient forms of dementia. The medicine is supposed to clean amyloid, the substance which is believed to harm nerve cells and lead to memory loss.